Herceptin FDA Approval History
FDA Approved: Yes (First approved September 25, 1998)
Brand name: Herceptin
Generic name: trastuzumab
Dosage form: Injection
Company: Genentech, Inc.
Treatment for: Breast Cancer, Gastric Cancer
Herceptin (trastuzumab) is a HER2/neu receptor antagonist indicated for the treatment of HER2 overexpressing breast cancer and for the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Development timeline for Herceptin
| Date | Article |
|---|---|
| Jun 3, 2023 | Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer |
| Oct 20, 2010 | Approval FDA Approves Herceptin For HER2-Positive Metastatic Stomach Cancer |
| Nov 16, 2006 | Approval FDA Approves Herceptin for the Adjuvant Treatment of HER2-Positive Node-Positive Breast Cancer |
| Sep 25, 1998 | Approval Herceptin: Biotechnology Breakthrough In Breast Cancer Wins FDA Approval |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.